T0	Participants 33 140	granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children:
T1	Participants 188 230	Japanese Cooperative Study Group of PBSCT.
T2	Participants 270 408	74 children who were scheduled to undergo high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT)
T3	Participants 603 735	The diagnosis included acute lymphoblastic leukemia (ALL) (n = 27), neuroblastoma (n = 29), and miscellaneous solid tumors (n = 18).
T4	Participants 736 972	Eligibility criteria included (1) primary PBSCT, (2) chemotherapy-responsive disease, and (3) collected cell number >1 x 10(5) colony-forming unit-granulocyte-macrophage (CFU-GM)/kg and >1 x 10(6) CD34(+) cells/kg patient's body weight.
T5	Participants 1008 1171	11 patients were excluded due to disease progression before PBSCT (n = 6) or a low number of harvested cells (n = 5), leaving 63 patients for analysis; 32 patients
T6	Participants 1703 1830	Five patients (two in the treatment group and three in the control group) were subsequently removed due to protocol violations.
T7	Participants 1853 1859	PBSCT.
T8	Participants 3372 3414	G-CSF therapy in children undergoing PBSCT